JAK2 and myeloproliferative neoplasm: Studies indicate that majority of cases with MPN have an overt positivity (>10%) of JAK2 V617F mutation, while in healthy individuals the mutational load is typically <1% of JAK2 V617F, with rare exemptional cases [20].